About
Joined as Chief Technical Officer in October 2018 and added Chief Operating Officer in February 2020; promoted to President and COO in September 2022. Resigned as President and COO effective December 31, 2025 and transitioned to a part-time Chief Technical Advisor role. Former SVP of Quality and Regulatory CMC at AveXis.
Roles
4D Molecular Therapeutics, Inc.
Former President and Chief Operating Officer; Chief Technical Advisor · Current role
2018–present
Fixed Compensation
FY 2025
All other compensation
$1,612
Total compensation
$1,441,573
Performance Compensation
Data from FY 2025
Cash incentive
Annual cash incentive
$339,513
Stock awards
Also at 4D Molecular Therapeutics, Inc.